Ocean Biomedical Inc OCEA

Healthcare Biotechnology

Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.

NDAQ:OCEA - Post by User

Ocean Biomedical Inc

<< Previous

Bullboard Posts

Next >>

Post by JasleenDhakaon May 04, 2023 5:44pm

80 Views

Post# 35431358

Anti-Chi3L1 antibody shows promising results

@OceanBiomedical's Anti-Chi3L1 antibody shows promising results, suppressing glioblastoma tumor growth by 60%. A major milestone as they file an application for human clinical trials with the FDA.

read this news: https://www.researchfrc.com/our-prediction-for-the-feds-meeting-this-week/

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity